Teen With Spina Bifida Inspires in the Face of Physical Adversity
'The doctor said, 'He's going to be a bright light and joy in this world. He is a blessing.''
As Manny, grew up, those words proved true.
Today, Manny, 15, is one of the most popular teenagers in his hometown in Minnesota where he spends his free time playing basketball and occasionally giving locker-room pep talks to some of his high school sports teams.
With his sense of humor, unwavering optimism, and the support of his loved ones, he continues to create the life of his dreams. In this episode of our series Open Book, Manny shares how spina bifida impacts his life in unseen ways.
Watch the video here.
Visit 3BL Media to see more multimedia and stories from Medtronic
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies
The 360 Quadrants analysis highlights the leaders in the global Smart Pills market, evaluating over 102 companies. Smart pills, also known as ingestible sensors or digital pills, offer revolutionary diagnostic functions and medication adherence monitoring by transmitting real-time data wirelessly. Key players include Medtronic, Olympus Corporation, and CapsoVision. The market's growth is driven by the demand for less invasive diagnostics and addressing medication non-adherence issues. Challenges include data privacy concerns, high costs, and regulatory complexities. Companies employ strategies like partnerships and tech integration to enhance market presence. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Smart Pills Company Evaluation" report has been added to offering. The Smart Pills Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Smart Pills. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. 360 Quadrants evaluated over 102 companies, of which the Top 14 Smart Pills Companies were categorized and recognized as quadrant pills, also known as ingestible sensors or digital pills, are revolutionary medical devices designed in the form of a swallowable capsule. Once ingested, these high-tech pills travel through the gastrointestinal (GI) tract to perform diagnostic functions or monitor treatment adherence. Common applications include capsule endoscopy, where a tiny camera captures images of the digestive system, and medication monitoring, where an embedded sensor signals when a pill has been taken. The data is transmitted wirelessly from inside the body to an external receiver, providing clinicians with unprecedented, real-time market for smart pills is primarily driven by the demand for less invasive diagnostic tools. Capsule endoscopy provides a patient-friendly and effective method for examining the small intestine, an area difficult to reach with traditional scopes. Another major driver is the pressing need to solve the multi-billion-dollar problem of medication non-adherence, especially for patients with chronic conditions. By providing objective confirmation that medication has been taken, smart pills can significantly improve disease management and clinical trial data accuracy. Continuous technological advancements are also making these devices more capable and their potential, smart pills face significant challenges. The security and privacy of the sensitive health data they collect and transmit are paramount concerns that must be rigorously addressed. The high cost of the pills and their associated monitoring systems can be a major barrier to widespread clinical use and reimbursement from insurance providers. The regulatory approval pathway for such novel devices is complex and lengthy. Technical hurdles, such as ensuring reliable data transmission through body tissue and extending the device's battery life, also remain areas of active 360 Quadrant maps the Smart Pills companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Smart Pills quadrant. The top criteria for product footprint evaluation included Target Area (Small Intestine, Large Intestine, Esophagus, Stomach), Application (Capsule Endoscopy, Patient Monitoring, Targeted Drug Delivery), Disease Indication (Crohn's Disease, Occult Gastrointestinal Bleeding, Small Bowel Tumors, Celiac Disease, Other Disease Indications), End User (Hospitals, Diagnostic Centers, Outpatient Settings, Other End Users) Key Players: Major vendors in the Smart Pills market are Medtronic (US), Olympus Corporation (Japan), and CapsoVision, Inc. (US), IntroMedic (South Korea and Shangxian Minimal Invasive Inc. (China), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (China), and AnX Robotics (US), etectRx (US), Check-Cap (Israel), and BodyCap (France). The key strategies major vendors implement in the Smart Pills market are partnerships, collaborations, product launches, and product enhancements. Medtronic Medtronic plc is a global titan in healthcare technology, with a dominant market position across its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios. The company is a leader in everything from pacemakers and insulin pumps to advanced surgical instruments. Strategically, Medtronic is focused on integrating AI, data analytics, and robotics - spearheaded by its HugoT surgical robot - into its offerings. Through active portfolio management and innovation in less-invasive technologies, the company aims to transform chronic disease management and surgical care worldwide, including in key growth markets like India. Olympus Corporation Olympus Corporation is the world's dominant leader in medical endoscopy, leveraging its legendary optical and digital expertise. The Japanese company provides a comprehensive range of endoscopes and therapeutic devices crucial for minimally invasive diagnosis and treatment in gastroenterology and other specialties. Strategically, Olympus has focused on becoming a pure-play medical technology company, divesting non-core assets. It is now heavily invested in integrating AI into its systems to enhance diagnostic accuracy and expanding its portfolio of therapeutic tools, solidifying its leadership in GI and beyond. CapsoVision, Inc CapsoVision, Inc. is an innovative medical device company specializing in gastrointestinal diagnostics through capsule endoscopy. Its flagship product, the CapsoCam Plus, sets itself apart with a unique 360-degree panoramic lateral camera, designed to provide a more comprehensive view of the small bowel. The company's strategy is to challenge established market players by leveraging this technological advantage and a simplified, data-recorder-free system for enhanced patient convenience. By focusing on improving diagnostic yield, CapsoVision aims to capture a growing share of the non-invasive GI imaging market. Key Topics Covered: 1 Introduction1.1 Market Definition1.2 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Demand for Non-Invasive Diagnostic Monitoring Devices3.2.1.2 Technological Advancements in Capsule Endoscopy3.2.1.3 Increasing Incidence of Colon Cancer3.2.2 Restraints3.2.2.1 High R&D Costs for Technological Developments and Advancements3.2.2.2 Low Accuracy and Reliability of Sensors and Cameras in Smart Pills3.2.3 Opportunities3.2.3.1 Innovations in Sensor Technologies and Wireless Communication3.2.3.2 Rising Need for Rapid Drug Delivery and Development3.2.4 Challenges3.2.4.1 Increased Patient Privacy and Data Security Concerns3.2.4.2 Shortage of Skilled Healthcare Professionals3.3 Industry Trends3.3.1 Advancements in Sensor Technologies3.3.2 Integration with Ai and Ml3.3.3 Integration with Wearable Devices3.4 Technology Analysis3.4.1 Key Technologies3.4.1.1 Wireless Communication Systems3.4.1.2 Sensor Technologies3.4.1.3 Self-Powered Ingestible Smart Pills3.4.1.4 Adaptive Frame Rate Technologies3.4.1.5 Imag3.4.1.6 Ai and Ml3.4.2 Complementary Technologies3.4.2.1 Robotic Technologies3.4.2.2 Data Analytics 3.4.3 Adjacent Technologies3.4.3.1 Iot3.4.3.2 Cloud Computing3.5 Trends/Disruptions Impacting Customer's Business3.6 Pipeline Analysis3.7 Porter's Five Forces Analysis3.8 Ecosystem Analysis3.9 Value Chain Analysis3.10 Patent Analysis3.10.1 Patent Publication Trends for Smart Pills3.10.2 Insights: Jurisdiction and Top Applicant Analysis3.10.3 List of Key Patents3.11 Key Conferences & Events, 2025-20263.12 Impact of Ai/Gen Ai on Smart Pills Market3.12.1 Key Use Cases3.12.2 Case Studies of Ai/Gen Ai Implementation3.12.2.1 Capsocam Sv-1 Versus Pillcam Sb3 to Detect Obscure Gastrointestinal Bleeding3.12.2.2 Aardex Group Partnered with Etectrx, Inc. to Track Medication-Taking Behaviors3.12.3 Impact of Ai/Gen Ai on Interconnected and Adjacent Ecosystems4 Competitive Landscape4.1 Introduction4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Smart Pills Market4.3 Revenue Analysis, 2019-20234.4 Market Share Analysis, 20234.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Application Footprint4.5.5.4 Target Area Footprint4.5.5.5 Disease Indication Footprint4.5.5.6 End-User Footprint4.5.5.7 Region Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Sme Players4.7 Company Valuation & Financial Metrics4.7.1 Financial Metrics4.7.2 Company Valuation4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product Launches, Approvals, and Enhancements4.9.2 Deals4.9.3 Other Developments5 Company Profiles Medtronic Olympus Corporation Capsovision, Inc. Intromedic Jinshan Science & Technology Anx Robotics Shenzhen Jifu Medical Technology Co., Ltd. Etectrx Bodycap Check-Cap Shangxian Minimal Invasive Inc. Veloce Corporation Biocam Endiatx Rf Co., Ltd. Celero Systems Biora Therapeutics, Inc. Innurvation Rani Therapeutics Motilis Medica Sa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk
The Saudi Arabia Blood Glucose Device Market is anticipated to grow from US$ 143.96 million in 2024 to US$ 259.8 million by 2033, exhibiting a CAGR of 6.78% from 2025-2033. This growth is fueled by rising diabetes incidence, increased health awareness, and government initiatives supporting early diagnosis and self-monitoring. Advances in Continuous Glucose Monitoring (CGM) systems and user-friendly glucometers enhance patient compliance. Key market players include Abbott Laboratories, Medtronic, and Dexcom Inc. The segment is bolstered by urban centers like Riyadh and Jeddah, reflecting strong market potential in Saudi Arabia. Saudi Arabian Blood Glucose Device Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Blood Glucose Device Market Size & Trends 2025-2033" report has been added to Saudi Arabia Blood Glucose Device Market is projected to grow at US$ 143.96 Million in 2024 to US$ 259.8 Million in 2033 at a CAGR of 6.78% over the forecast period 2025-2033. The market is fueled by the increasing incidence of diabetes, increasing awareness about health, and government initiatives for early diagnosis and self-blood glucose monitoring. Recent advances in continuous glucose monitoring (CGM) systems and easy-to-use glucometers are enhancing patient compliance and results. In Saudi Arabia, blood glucose meters have become very popular as a result of the high and increasing rate of diabetes, which is one of the topmost public health problems in the country. Lifestyle issues such as lack of physical activity, high-calorie diets, and rising obesity levels have fueled this phenomenon. The government has initiated various awareness campaigns and public health programs promoting early detection and self-management. Moreover, easy access to blood glucose monitors through pharmacies and online stores, insurance coverage, and technological advances has exposed them to both urban and rural communities throughout the Drivers in the Saudi Arabia Blood Glucose Device Market Increased Type 2 Diabetes PrevalenceSaudi Arabia has a very high rate of diabetes prevalence in the world, and Type 2 diabetes is prevalent among most of the adult population. Inactive lifestyles, poor eating habits, and growing obesity levels are the key causes. With rising awareness, more people are opting for blood glucose meters for regular monitoring and early treatment. The government as well as the healthcare sector is also placing emphasis on self-care to prevent complications and healthcare expenses, thereby increasing demand burden of chronic disease is likely to fuel steady expansion in the blood glucose device market during the forecast period. Over one in ten individuals in Saudi Arabia had diabetes, and the disease's prevalence was set to nearly double by the year 2045, as stated in the IDF report. The report also stated that 4.27 million individuals in Saudi Arabia, a country with a population of approximately 34.8 million, suffer from diabetes, whereas an additional 1.86 million have the condition but are not diagnosed yet. The number is predicted to rise to 5.6 million in 2030 and continue to rise to 7.5 million in Advancements and User-Friendly DevicesThe ready availability of modern blood glucose monitors, including Continuous Glucose Monitoring (CGM) systems and Bluetooth glucometers, is transforming the management of diabetes. They are providing better accuracy, real-time monitoring, and smartphone connectivity, enabling improved diabetes management. Simple-to-use interfaces, smaller sizes, and painless testing techniques enhance their appeal to younger and older global players make an entry into the Saudi market with state-of-the-art innovations, patients gain through enhanced choices that enhance compliance and enhance long-term results, fuelling adoption across age ranges. August 2023, Nemaura Medical received authorization by the Saudi Food and Drug Authority (SFDA) for its non-invasive glucose sensor wearable, sugarBEAT. Regarded as a Class IIb medicinal device with a CE mark, the device offers useful information using daylong glucose monitoring and review of daily glucose Programs and Public Health CampaignsVision 2030 health sector reform is being heavily funded by the government of Saudi Arabia with a focus on disease prevention and early detection. Screening programs for diabetes, school and workplace awareness programs, and collaboration with healthcare providers are enhancing diagnosis rates and encouraging frequent glucose for the necessary medical equipment and insurance coverage for diabetes care have further enhanced access to blood glucose equipment. Monitoring equipment is also being more commonly installed in hospitals and primary care forward-looking initiatives by the public sector are fast-tracking market penetration and promoting the adoption of blood glucose monitoring devices across the board. For example, in 2024, the Saudi Ministry of Health collaborated with Ithnain to improve diabetes control, launching innovative coaching for more than 10,000 patients and keeping in line with Vision 2030 to develop healthcare solutions throughout the Kingdom. This program is consistent with Saudi national health policies for Vision 2030 and reflects Saudi Arabia's increasing interest in diabetes awareness and effective in the Saudi Arabia Blood Glucose Device Market Excessive Cost of Sophisticated DevicesIn spite of the benefits of CGMs and intelligent glucometers, their excessive cost is a deterrent for most consumers. High-tech blood glucose devices with digital capabilities or continuous monitoring features tend to have a higher cost, and not all health insurance plans provide full coverage. The premium pricing issue disproportionately targets low - and middle-income patients, making regular monitoring less many continue to use less efficient or older monitoring devices. Without increased affordability or wider insurance cover, widespread use of high-tech blood glucose devices is a major hurdle in the Compliance and Awareness in Rural RegionsDespite good healthcare facilities and awareness campaigns in urban areas such as Riyadh and Jeddah, rural and remote areas lack proper awareness and access to diabetes care. Poor compliance due to limited understanding of the necessity for frequent glucose monitoring and how to use the devices effectively contributes to this. Some patients also lack technical competence for newer differences impact early diagnosis and continuation disease management. Widening outreach, education, and distribution to underserved communities is an essential barrier to achieving countrywide use of blood glucose monitoring technologies. Key Players Analysis (Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis) Abbott Laboratories Medtronic Dexcom Inc. B. Braun Melsungen AG DarioHealth Corp Sanofi Bionime Corporation Novo Nordisk Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $143.96 Million Forecasted Market Value (USD) by 2033 $259.8 Million Compound Annual Growth Rate 6.7% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Blood Glucose Device Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Products6.2 By Application6.3 By End User6.4 By States7. Product7.1 Test Strips7.2 Lancets7.3 Blood Glucose Meters8. Application8.1 Type 1 Diabetes8.2 Type 2 Diabetes8.3 Gestational Diabetes9. End User9.1 Hospital Pharmacies9.2 Retail Pharmacies9.3 Online Sales9.4 Diabetes Clinics & Centers10. Top States10.1 Dhahran10.2 Riyadh10.3 Khobar10.4 Jeddah10.5 Dammam10.6 Others11. Reimbursement Policy12. Value Chain Analysis13. Porter's Five Forces Analysis13.1 Bargaining Power of Buyers13.2 Bargaining Power of Suppliers13.3 Degree of Competition13.4 Threat of New Entrants13.5 Threat of Substitutes14. SWOT Analysis14.1 Strength14.2 Weakness14.3 Opportunity14.4 Threats15. Pricing Benchmark Analysis15.1 Abbott Laboratories15.2 Medtronic15.3 Dexcom, Inc.15.4 B. Braun Melsungen AG15.5 DarioHealth Corp15.6 Sanofi15.7 Bionime Corporation15.8 Novo Nordisk16. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Blood Glucose Device Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a day ago
- Yahoo
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
Key Points Healthcare is an important and growing industry with products that are inherently necessary. If you are starting early, you can swing for the fences and hope you hit one out of the park, or buy a collection of companies that routinely hit singles and doubles. Most investors will be better off finding healthcare stocks that have proven themselves over time, like this trio of high-yielding industry leaders. 10 stocks we like better than Medtronic › If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but that could entail more risk than you think. Make a big bet on the wrong stock and you could turn thousands of dollars into pennies. An alternative path that might make more sense is to find a collection of industry leaders in an inherently growth-oriented industry to invest in. The healthcare industry is a great example, since everyone needs medical care and technological advances drive the sector's growth. And, lucky for you, industry leaders Medtronic (NYSE: MDT), Johnson & Johnson (NYSE: JNJ), and Merck (NYSE: MRK) are all attractively priced right now. Here's why younger investors might want to buy all three of these healthcare stocks. 1. Medtronic is taking care of some normal maintenance Medtronic is one of the largest medical device makers on the planet. It has industry-leading positions in the cardiovascular, neuroscience, medical surgical, and diabetes niches. The company's growth has stalled out. That has left Wall Street downbeat on the shares, which trade down around 30% from their 2021 highs. The dividend yield is near historical highs at around 3%. Why buy this down-and-out stock? Because Medtronic has a long history of surviving through the hard times that every company eventually has to face. The proof of this is its 48 consecutive years' worth of annual dividend increases. That's an incredible streak that places the company just two years shy of Dividend King status. More important today, however, is that management is taking the steps necessary to improve profitability. That includes cutting costs, investing in new technologies and products, and refocusing its business around its most profitable operations. The next big move is the spin-off of the company's diabetes business, which is set to take place in early 2026. If you don't mind collecting a lofty yield from a company that knows how to survive hard times, Medtronic is a great pick if you are 20 or 65. But if you are 20, you can benefit from decades of business growth and use a dividend reinvestment plan to further compound your returns. 2. Johnson & Johnson will survive the talcum powder mess Next up on this list is Johnson & Johnson, which is a giant in both the pharmaceutical and medical device spaces. Like Medtronic, it is out of favor with investors. The stock's dividend yield is 3% and toward the high side of the historical yield range. The average pharmaceutical stock has a yield of around 1.4% while the average healthcare stock's yield is roughly 1.8%. The stock price, however, isn't quite as downtrodden as that of Medtronic, with J&J's price down from its all-time high by roughly 5% or so. That said, there is a material overhang here in the form of talcum powder lawsuits that have been filed against J&J. There are billions of dollars at stake, and the company can't fully discuss the issue with shareholders because of the legal nature of the problem. The uncertainty has left J&J shares to languish a bit. But this Dividend King has increased its dividend annually for over six consecutive decades, showing clearly that it knows how to survive hard times. To be fair, there are also headwinds to deal with in the company's core operations. The list includes patent expirations and the need to keep bringing out new drugs and medical devices. But those are just normal business fluctuations, much like what Medtronic is dealing with. Adding the legal issue probably makes J&J more appropriate for aggressive investors or those who can stick around for a long time. Like investors in their 20's. 3. Merck has a patent cliff coming up Medtronic is focused on medical devices. Johnson & Johnson's specialties are medical devices and drugs. Merck is just drugs. And while it doesn't have as long a history of annual dividend increases, at just 15 years, Merck's dividend has trended generally higher for decades. It doesn't exactly stand toe to toe with Medtronic and J&J on the dividend front, but it is still a reliable business that has proven it can muddle through hard times. It is facing a hard time right now. First, there's a rather negative view of healthcare companies in the market related to political and social issues involving the current administration. Given the importance of healthcare in general, and drugs in particular, this will likely pass. The second problem for Merck is that its growth is heavily influenced by one oncology drug -- Keytruda. In a few years, however, this drug will lose patent protections and Merck will need to have other drugs lined up to make up for the revenue that generic drugs tend to steal away. Merck's pipeline looks a bit weak, so investors are worried it won't be ready for the approaching patent cliff. That's not unreasonable, but Merck has world-class R&D teams, and it is large enough to buy smaller competitors with attractive products (if it needs to). It is highly likely that it figures out how to deal with the patent issue, like it has many times before. Still, investors are downbeat at the moment, and the stock is off its 2024 highs by nearly 40% and the dividend yield is a historically high 4% or so. If you have the benefit of time, you can buy now and comfortably wait for better days. The key to the healthcare story There are two broad ways to play the healthcare sector. You can swing for the fences and buy small upstarts with novel products, hoping that the companies you pick are the ones that end up winning in the market. Or you can buy industry leaders that have proven time and again that they have the wherewithal to survive and thrive over the long term, often buying up the upstarts to benefit from their novel products. Most investors will be better off focusing on the industry leaders. And, often, the best time to buy industry leaders is when investors are downbeat on their prospects. Which is exactly the case today with industry giants Medtronic, Johnson & Johnson, and Merck. If you buy in while you are in your 20s and hold until you retire (hopefully reinvesting dividends all along the way), history suggests you will end up a very happy shareholder. Should you buy stock in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. If You're In Your 20's, Consider Buying These 3 Healthcare Stocks was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
